Create a free account to get access to stock details and our dividend tracker
We won't send you any spam and we don't want a credit card.
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
The company also develops Protega, a peripheral blood-based test that aims to predict the risk of fibrosis and long-term graft failure.
Based on sector and market capitalization